Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. / Börcsök, Judit; Sztupinszki, Zsofia; Bekele, Raie; Gao, Sizhi P; Diossy, Miklos; Samant, Amruta S; Dillon, Kasia M; Tisza, Viktoria; Spisák, Sándor; Rusz, Orsolya; Csabai, Istvan; Pappot, Helle; Frazier, Zoë J; Konieczkowski, David J; Liu, David; Vasani, Naresh; Rodrigues, James A; Solit, David B; Hoffman-Censits, Jean H; Plimack, Elizabeth R; Rosenberg, Jonathan E; Lazaro, Jean-Bernard; Taplin, Mary-Ellen; Iyer, Gopa; Brunak, Søren; Lozsa, Rita; Van Allen, Eliezer M; Szüts, Dávid; Mouw, Kent W; Szallasi, Zoltan.
In: Clinical Cancer Research, Vol. 27, No. 7, 2021, p. 2011-2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer
AU - Börcsök, Judit
AU - Sztupinszki, Zsofia
AU - Bekele, Raie
AU - Gao, Sizhi P
AU - Diossy, Miklos
AU - Samant, Amruta S
AU - Dillon, Kasia M
AU - Tisza, Viktoria
AU - Spisák, Sándor
AU - Rusz, Orsolya
AU - Csabai, Istvan
AU - Pappot, Helle
AU - Frazier, Zoë J
AU - Konieczkowski, David J
AU - Liu, David
AU - Vasani, Naresh
AU - Rodrigues, James A
AU - Solit, David B
AU - Hoffman-Censits, Jean H
AU - Plimack, Elizabeth R
AU - Rosenberg, Jonathan E
AU - Lazaro, Jean-Bernard
AU - Taplin, Mary-Ellen
AU - Iyer, Gopa
AU - Brunak, Søren
AU - Lozsa, Rita
AU - Van Allen, Eliezer M
AU - Szüts, Dávid
AU - Mouw, Kent W
AU - Szallasi, Zoltan
PY - 2021
Y1 - 2021
N2 - PURPOSE: Cisplatin-based chemotherapy is a first-line treatment for muscle-invasive and metastatic urothelial cancer. Approximately 10% of bladder urothelial tumors have a somatic missense mutation in the nucleotide excision repair (NER) gene, ERCC2, which confers increased sensitivity to cisplatin-based chemotherapy. However, a significant subset of patients is ineligible to receive cisplatin-based therapy due to medical contraindications, and no NER-targeted approaches are available for platinum-ineligible or platinum-refractory ERCC2-mutant cases.EXPERIMENTAL DESIGN: We used a series of NER-proficient and NER-deficient preclinical tumor models to test sensitivity to irofulven, an abandoned anticancer agent. In addition, we used available clinical and sequencing data from multiple urothelial tumor cohorts to develop and validate a composite mutational signature of ERCC2 deficiency and cisplatin sensitivity.RESULTS: We identified a novel synthetic lethal relationship between tumor NER deficiency and sensitivity to irofulven. Irofulven specifically targets cells with inactivation of the transcription-coupled NER (TC-NER) pathway and leads to robust responses in vitro and in vivo, including in models with acquired cisplatin resistance, while having minimal effect on cells with intact NER. We also found that a composite mutational signature of ERCC2 deficiency was strongly associated with cisplatin response in patients and was also associated with cisplatin and irofulven sensitivity in preclinical models.CONCLUSIONS: Tumor NER deficiency confers sensitivity to irofulven, a previously abandoned anticancer agent, with minimal activity in NER-proficient cells. A composite mutational signature of NER deficiency may be useful in identifying patients likely to respond to NER-targeting agents, including cisplatin and irofulven.See related commentary by Jiang and Greenberg, p. 1833.
AB - PURPOSE: Cisplatin-based chemotherapy is a first-line treatment for muscle-invasive and metastatic urothelial cancer. Approximately 10% of bladder urothelial tumors have a somatic missense mutation in the nucleotide excision repair (NER) gene, ERCC2, which confers increased sensitivity to cisplatin-based chemotherapy. However, a significant subset of patients is ineligible to receive cisplatin-based therapy due to medical contraindications, and no NER-targeted approaches are available for platinum-ineligible or platinum-refractory ERCC2-mutant cases.EXPERIMENTAL DESIGN: We used a series of NER-proficient and NER-deficient preclinical tumor models to test sensitivity to irofulven, an abandoned anticancer agent. In addition, we used available clinical and sequencing data from multiple urothelial tumor cohorts to develop and validate a composite mutational signature of ERCC2 deficiency and cisplatin sensitivity.RESULTS: We identified a novel synthetic lethal relationship between tumor NER deficiency and sensitivity to irofulven. Irofulven specifically targets cells with inactivation of the transcription-coupled NER (TC-NER) pathway and leads to robust responses in vitro and in vivo, including in models with acquired cisplatin resistance, while having minimal effect on cells with intact NER. We also found that a composite mutational signature of ERCC2 deficiency was strongly associated with cisplatin response in patients and was also associated with cisplatin and irofulven sensitivity in preclinical models.CONCLUSIONS: Tumor NER deficiency confers sensitivity to irofulven, a previously abandoned anticancer agent, with minimal activity in NER-proficient cells. A composite mutational signature of NER deficiency may be useful in identifying patients likely to respond to NER-targeting agents, including cisplatin and irofulven.See related commentary by Jiang and Greenberg, p. 1833.
U2 - 10.1158/1078-0432.CCR-20-3316
DO - 10.1158/1078-0432.CCR-20-3316
M3 - Journal article
C2 - 33208343
VL - 27
SP - 2011
EP - 2022
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 7
ER -
ID: 260353678